Business Description
WuXi Biologics (Cayman) Inc
ISIN : KYG970081090
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.47 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 1.05 | |||||
Interest Coverage | 28.08 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.04 | |||||
Beneish M-Score | -2.38 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 52 | |||||
3-Year EBITDA Growth Rate | 60.9 | |||||
3-Year EPS without NRI Growth Rate | 55.8 | |||||
3-Year FCF Growth Rate | 47.2 | |||||
3-Year Book Growth Rate | 36.2 | |||||
Future 3-5Y EPS without NRI Growth Rate | 14.98 | |||||
Future 3-5Y Total Revenue Growth Rate | 14.4 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 31.93 | |||||
9-Day RSI | 35.08 | |||||
14-Day RSI | 36.79 | |||||
6-1 Month Momentum % | -69.29 | |||||
12-1 Month Momentum % | -69.72 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.78 | |||||
Quick Ratio | 2.54 | |||||
Cash Ratio | 1.47 | |||||
Days Inventory | 72.23 | |||||
Days Sales Outstanding | 108.98 | |||||
Days Payable | 26.43 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.9 | |||||
Shareholder Yield % | 4.22 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 40.08 | |||||
Operating Margin % | 26.13 | |||||
Net Margin % | 19.96 | |||||
FCF Margin % | 6.54 | |||||
ROE % | 8.96 | |||||
ROA % | 6.4 | |||||
ROIC % | 9.42 | |||||
ROC (Joel Greenblatt) % | 14.37 | |||||
ROCE % | 9.7 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 15.53 | |||||
Forward PE Ratio | 11.96 | |||||
PE Ratio without NRI | 13.24 | |||||
Price-to-Owner-Earnings | 55.53 | |||||
PEG Ratio | 0.21 | |||||
PS Ratio | 3.07 | |||||
PB Ratio | 1.26 | |||||
Price-to-Tangible-Book | 1.33 | |||||
Price-to-Free-Cash-Flow | 47.18 | |||||
Price-to-Operating-Cash-Flow | 7.58 | |||||
EV-to-EBIT | 10.11 | |||||
EV-to-Forward-EBIT | 8.99 | |||||
EV-to-EBITDA | 10.11 | |||||
EV-to-Forward-EBITDA | 7.35 | |||||
EV-to-Revenue | 2.57 | |||||
EV-to-Forward-Revenue | 2.37 | |||||
EV-to-FCF | 38.14 | |||||
Price-to-Projected-FCF | 18.2 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.4 | |||||
Price-to-Graham-Number | 0.86 | |||||
Price-to-Net-Current-Asset-Value | 10.03 | |||||
Earnings Yield (Greenblatt) % | 9.89 | |||||
FCF Yield % | 2.24 | |||||
Forward Rate of Return (Yacktman) % | 15.98 |